Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|January 6, 2006
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registryArthur L Weaver, Richard L Lautzenheiser, Michael H Schiff, et al.
The Journal of Rheumatology|April 3, 2003
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial resultsRoy M Fleischmann, Scott W Baumgartner, Elizabeth A Tindall, et al.
The Journal of Rheumatology|June 2, 2004
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritisKaren E Hansen, Julie P Hildebrand, Mark C Genovese, et al.
The Journal of Rheumatology|February 17, 2006
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind studyAlyssa K Johnsen, Michael H Schiff, Philip J Mease, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
Arthritis and Rheumatism|June 28, 2006
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trialDésirée van der Heijde, Alan Kivitz, Michael H Schiff, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
Arthritis and Rheumatism|July 13, 2002
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese, Joan M Bathon, Richard W Martin, et al.
Pageof 4